StockDuty ← Dashboard Oct 01, 2026 10:56 AM ET
SignalFDA/Bio

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

Pfizer's Tilrekimig achieved significant skin clearance in Phase 2 atopic dermatitis study.

What changed
Pfizer's Tilrekimig achieved significant skin clearance in Phase 2 atopic dermatitis study.
Why it matters
Pfizer's Tilrekimig achieved significant skin clearance in Phase 2 atopic dermatitis study. — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →